Multifunctional Radical Quenchers for the Treatment of Friedreich's Ataxia Multifunctional Radical Quenchers for the Treatment of Friedreich's Ataxia The objectives for this project are based on the belief that the absence of frataxin in Friedreichs Ataxia patients leads to progressive mitochondrial dysfunction and concomitant oxidative stress, resulting in increasing degradation of the mitochondrion, especially the mitochondrial (and cell) membranes, and probably in diminished ATP production. The objectives of this project involve the implementation of a strategy, for which proof-of-principle has already been obtained, to develop therapeutic agents that can be used to blunt mitochondrial degradation resulting from oxidative stress, and to augment ATP production in partially dysfunctional mitochondria. These agents should be broadly applicable to the treatment of diseases involving mitochondrial dysfunction within the electron transport chain.
|Effective start/end date||6/5/10 → 12/31/11|
- Friedreich's Ataxia Research Alliance: $350,000.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.